Comparing the current results to its competitors, Therapeuticsmd Inc reported Revenue decrease in the 2 quarter 2026 year on year by -8.72 %, despite the revenue increase by the most of its competitors of 5.78 %, recorded in the same quarter.
Therapeuticsmd Inc Net Income in the 2 quarter 2026 fell year on year by -71.87%, while most of its competitors have experienced a contraction in net income by -78.01 %.
May 13, 2024
TherapeuticsMD, Inc., a company that notably owns the rights to pharmaceutical royalties (NASDAQ: TXMD), has recently announced their first quarter financial results for the fiscal year 2024. As a respected journal in the field of scientific inquiry and pharmaceutical advancements, we deem it crucial to conduct an extensive review of this eminently influential industry player, juxtaposing its financial performance with its rivals.According to the financial results released, the financial disposition of TherapeuticsMD in the first quarter ended March 31, 2024, was characterized by a net loss from continuing operations, set at $(0.8) million, or $(0.07) per basic and diluted common share. In comparison to the ...
May 12, 2024
TherapeuticsMD Reports First Quarter 2024 Financial Results with Net Loss from Continuing OperationsTherapeuticsMD, Inc. (TherapeuticsMD or the Company) (NASDAQ: TXMD) recently released its financial results for the first quarter ending March 31, 2024. The company reported a net loss from continuing operations of $0.8 million, or $0.07 per basic and diluted common share, compared to a net loss of $2.3 million, or $0.XX per share, for the same period in the previous year.Despite the reported net loss, TherapeuticsMD has faced tough competition from its peers. Comparing the current results to its competitors, the company experienced a 0% decrease in revenue in the third quarter of 2023, while its competitors r...
May 10, 2024
As the first quarter of 2024 concludes, TherapeuticsMD, Inc. (NASDAQ: TXMD), a healthcare-focused company specialising in securing royalties for pharmaceutical products, has made considerable strides towards achieving its financial goals. However, an insightful look into the specifics reveals a mix of wins and losses, suggesting that the journey ahead may still have a few hurdles.In the first quarter ended March 31, 2024, TherapeuticsMD reported a net loss from continuing operations of $(0.8) million, equivalent to $(0.07) per basic and diluted share. This constitutes an improvement when compared to the comparative quarter of previous year where the net loss was $(2.3) million, implying a reduction in losses...
Prothena Corporation Public Limited Company Share Performance
+10.09%
This Quarter
Prothena Corporation Public Limited Company
Profile
Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Pharming Group N.V. operates on a business model focused on the development, production, and commercialization of innovative therapeutic products for the treatment of rare diseases and unmet medical needs. The company primarily generates revenue by selling its approved products in various geographic markets and through strategic collaborations with pharmaceutical partners. Pharming Group N.V. also engages in research and development activities to expand its product pipeline and explore potential new treatments.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Therapeuticsmd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Therapeuticsmd Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
